<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2005</study_start_year><condition>Colonic Neoplasms</condition><disease>Colonic Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2018907</full_dataset_link><location>Sweden</location><location>Denmark</location><study_start_month>8</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Enzastaurin for Patients With Metastatic Colorectal Cancer</name><description>Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer</description><dates><creation>2005-08-15</creation></dates><accession>2018907</accession><cross_references><ClinicalTrials___gov>NCT00192114</ClinicalTrials___gov></cross_references></HashMap>